• Latest
    • Big pharma
    • Biotechnology
    • CRISPR
    • Generics
    • Unified Patent Court
  • Regions
    • Americas
    • Europe
    • Asia
    • Asia-Pacific
  • Careers
  • Events
    • Conferences
    • Conference Videos
    • Webinars
  • Directory
  • Magazines
  • About
  • Contact
  • Newsletter
  • Login
  • Subscribe
  • Home
  • About
  • Contact
  • Newsletter
  • Login


Request Trial
  • Home
  • Copyright compliance in the life sciences industry
race-uphill-sand-dune
31 March 2014Kate Alzapiedi

Copyright compliance in the life sciences industry

Now that the rapid exchange of scientific research and product information across international borders has become commonplace, rights holders and users of published material face an increasingly complex set of issues involving reuse rights, permissions, restrictions and fees.

Already registered?

Login to your account


If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.

For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Careers
Senior USPTO solicitor steps into private practice
14 January 2026   A high-profile departure from the USPTO sees a senior appellate expert move into private practice as demand increases in the firm's life sciences IP practice.
Careers
Goodwin targets transatlantic patent work with London hire
14 January 2026   The US firm has recruited a European patent attorney with three decades of experience to build its patent prosecution offering across the continent.
Europe
Bayer secures key Denmark ruling as Xarelto faces expiry pressure
13 January 2026   As the drug moves deeper into its post-exclusivity phase, a Nordic decision highlights the value of secondary patents, presumption of validity, and interim relief when a drug's core patents expire.


Editor's picks

Deadline extended: Who are the world’s best in-house counsel?
Europe
Deadline extended: Who are the world’s best in-house counsel?
9 January 2026

Editor's picks

Europe
Deadline extended: Who are the world’s best in-house counsel?
9 January 2026
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025
Europe
Abbott appeals ‘baffling’ decision in glucose monitoring device feud
16 December 2025
Americas
Teva scrubs 200-plus Orange Book patents after FTC turns the screw
11 December 2025
Americas
US govt backs Hikma over ‘skinny label’ rules
9 December 2025
Big Pharma
The clinical trial dilemma: Navigating European practice
27 November 2025

More features

How AI will be shaped by legal and regulatory developments in 2026
Deadline extended: Who are the world’s best in-house counsel?
Bird & Bird targets Nordic life sciences growth with regulatory hire
Key EU and UK regulatory changes to watch for in 2026
Regeneron v Alvotech: The big impact
Beyond traditional IP: A comprehensive AI strategy for life sciences
Prosecuting bispecific antibody patents: A cookbook for patent chefs
Marks & Clerk adds multi-jurisdictional disputes expert

  • Home
  • News
  • About us
  • Contact
  • Terms of Use
  • Privacy Policy
  • Terms of Subscription

LSIPR
Newton Media Ltd
Kingfisher House
21-23 Elmfield Road
BR1 1LT
United Kingdom

  • Twitter
  • Linkedin